Skip to content

MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523349-86-00
Enrollment
700
Registered
2026-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Brief summary

Proportion of patients achieving pain relief, i.e. pain intensity score on visual analogic scale (VAS) ≤ 3 at 30 minutes.

Detailed description

Pain relief: time before achieving pain relief, i.e. time between randomization and pain intensity score on VAS ≤ 3;, Pain relief: time to reach initial pain divided by two (initial VAS / 2), Impact of the treatments on cardiovascular system: heart rate, arterial blood pressure, pulse oximetry and ECG changes at hospital arrival, Tolerance of the treatments: respiratory depression: respiratory rate < 10 cycles per minutes, Tolerance of the treatments: sedation: Richmond Agitation - Sedation Scale (RASS) ≥ 2 or ≤ -2, Tolerance of the treatments: : dizziness, pruritus, nausea, vomiting, headache

Interventions

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Proportion of patients achieving pain relief, i.e. pain intensity score on visual analogic scale (VAS) ≤ 3 at 30 minutes.

Secondary

MeasureTime frame
Pain relief: time before achieving pain relief, i.e. time between randomization and pain intensity score on VAS ≤ 3;, Pain relief: time to reach initial pain divided by two (initial VAS / 2), Impact of the treatments on cardiovascular system: heart rate, arterial blood pressure, pulse oximetry and ECG changes at hospital arrival, Tolerance of the treatments: respiratory depression: respiratory rate < 10 cycles per minutes, Tolerance of the treatments: sedation: Richmond Agitation - Sedation Scale (RASS) ≥ 2 or ≤ -2, Tolerance of the treatments: : dizziness, pruritus, nausea, vomiting, headache

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026